Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2016. The document serves as a transaction notification regarding a specific event involving a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific executive compensation transaction:
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award Plan.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 17,489 notional ordinary shares.
- Price: £16.4675 per share.
- Total Value: £288,000.11 (gross, before tax withholding).
Material Changes
The filing reports a single transaction event: the vesting of an award made on September 24, 2014, for Mr. N Hirons (SVP, Global Ethics & Compliance) on August 26, 2016. There is no information provided regarding material changes to the company's overall financial position or operations compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of an insider transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR involved: Mr. N Hirons, SVP, Global Ethics & Compliance.
- Confirm the vesting date of the award: August 26, 2016.
- Note that the transaction resulted in a cash payment rather than a direct share issuance, based on 17,489 notional shares.
- Understand that this filing does not reflect the company's broader financial performance for the period.